首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   166篇
  免费   19篇
林业   7篇
  5篇
综合类   27篇
农作物   6篇
水产渔业   4篇
畜牧兽医   128篇
园艺   1篇
植物保护   7篇
  2023年   1篇
  2022年   1篇
  2021年   4篇
  2020年   4篇
  2019年   4篇
  2018年   2篇
  2017年   6篇
  2016年   3篇
  2015年   7篇
  2014年   2篇
  2013年   14篇
  2012年   9篇
  2011年   5篇
  2010年   9篇
  2009年   9篇
  2008年   7篇
  2007年   9篇
  2006年   8篇
  2005年   5篇
  2004年   8篇
  2003年   4篇
  2002年   1篇
  2001年   1篇
  2000年   2篇
  1999年   1篇
  1998年   7篇
  1997年   4篇
  1996年   3篇
  1995年   3篇
  1994年   2篇
  1993年   2篇
  1992年   1篇
  1991年   5篇
  1990年   3篇
  1989年   5篇
  1988年   2篇
  1987年   1篇
  1986年   3篇
  1985年   1篇
  1984年   1篇
  1983年   3篇
  1982年   1篇
  1974年   1篇
  1973年   2篇
  1972年   2篇
  1971年   1篇
  1970年   3篇
  1969年   1篇
  1966年   1篇
  1926年   1篇
排序方式: 共有185条查询结果,搜索用时 187 毫秒
81.
Objective: To assess the efficacy and safety of a formulation containing moxidectin and 6 in 1 vaccine in sheep under field conditions.
Design: Efficacy and safety study.
Animals: Two hundred and five crossbred Merino lambs and two hundred and eight Merino ewes were used in the studies.
Procedure: A formulation was made for the simultaneous treatment of sheep with moxidectin and immunisation against clostridial diseases and caseous lymphadenitis. The efficacy against nematodes, vaccine response and safety were assessed.
Results: Effective control of nematodes and responses to antigens were achieved following subcutaneous administration. The formulation was safe to administer; occasional minor tissue reactions were evident, but no other adverse effects of treatment were observed in either pregnant ewes or lambs, using either the recommended dose, or an overdose of the formulation.
Conclusion: Administration of a formulation containing moxidectin, five clostridial antigens and caseous lymphadenitis antigen proved safe and efficacious under field conditions.  相似文献   
82.
Objectives of this study were to characterize patterns of follicular development in sheep superovulated with purified follicle stimulating hormone (FSH) (OVAGENTM, ICP, Auckland, New Zealand) and to determine its influence on preovulatory events (onset of the oestrus behaviour and timing of the preovulatory luteinizing hormone surge) and ovarian response (ovulation rate and embryo yield). Number and size of all ≥ 23 mm follicles from the first FSH injection to withdrawal of progestagen sponges was determined by transrectal ultrasonography just prior to every FSH injection in nine Manchega ewes superovulated with eight decreasing doses (ml) (1.5 × 3, 1.25 × 2 and 1 × 3) of OVAGEN injected twice daily from 60 h before to 24 h after the withdrawal of 40 mg fluorogestone acetate sponges. Oestrous detection and jugular blood sampling for LH radioimmunoassay were performed every 3 h from 14 to 53 h after sponge removal and ovulation rate and number of embryos were determined 4 days after progestagen withdrawal. Administration of OVAGEN induced a significant rise (p < 0.0005) in the number of follicles ≥ 4 mm in size because of an increased growth in size of follicles from the first FSH injection to sponge removal, an increase in the number of newly detected follicles from 12 to 36 h of the first FSH dose (p < 0.005) and a decrease in regression rate from 24 h (p < 0.001). The number of follicles 2–3 mm in size at first FSH dose (10.4 ± 1.5) was positively correlated with the number of ≥ 4 mm follicles at 0 h (19.0 ± 2.7, p < 0.01). A higher number of ≥ 4 mm follicles at 0 h was related with an earlier appearance of oestrus (31.5 ± 1.5 h, p = 0.08) and LH surge (45.0 ± 2.3 h, p < 0.005), and a higher ovulation rate (18.2 ± 3.8, p < 0.005). On the other hand, the rate of embryo recovery was decreased in ewes with earlier preovulatory LH peaks (p < 0.005), with a shorter interval between oestrus and LH peak (p < 0.05).  相似文献   
83.
84.
The aim of this study was to determine the association between the oestrous response of pre‐pubertal gilts to gonadotrophin injection or boar exposure and their subsequent farrowing rate and litter size. At 154 days of age, randomly selected pre‐pubertal gilts received an intramuscular injection of 400 IU equine chorionic gonadotrophin plus 200 IU human chorionic gonadotrophin (PG600®; Merck Animal Health; n = 181). From the remaining pool of animals not treated with hormones, the first gilts showing signs of oestrus were selected to act as controls (n = 201). Boar exposure began at 155 days of age for both groups, and gilts were bred at a weight of approximately 130 kg. Comparisons were made between PG600®‐treated gilts exhibiting oestrus or not within 7 days post‐injection (early and late responders, respectively) and control gilts exhibiting oestrus or not within 30 days after beginning of boar exposure (select and non‐select control gilts, respectively). By 162 days, oestrus was detected in 67.5% of PG600®‐treated gilts compared with 5.7% of control gilts (p < 0.0001). The proportion of animals observed in oestrus at least three times before breeding was greater for select control gilts compared with early and late responder PG600®‐treated gilts (p  0.001). There were no significant differences in farrowing rate and litter size between the four treatment groups. These data indicate that PG600® is an effective tool to induce an earlier oestrus in gilts, that subsequent farrowing rate and born alive litter size compare favourably to that of select gilts and that gilts failing to respond promptly to hormonal stimulation do not exhibit compromised fertility.  相似文献   
85.
To meet weekly breeding targets, it is occasionally necessary to inject exogenous gonadotrophins to induce oestrus in prepubertal gilts. However, the gilt oestrus response to equine chorionic gonadotrophin (eCG) either alone or in combination with human chorionic gonadotrophin (hCG) can be unpredictable. The objective of the present study was to examine possible reasons for this unpredictability. Prepubertal gilts (90 kg and 153 days of age, n = 109) received an injection of either 600 IU eCG or a combination of 400 IU eCG and 200 IU hCG (PG600), or were non-injected controls, and were then exposed to a mature boar for 15 min daily for 7 days for oestrus detection. At the time of injection, real-time ultrasound revealed that the gilt ovaries had primarily 1–2 mm follicles. Blood samples were obtained at time of hormone injection (day 0) and at days 3, 7 and 10 for assay of serum progesterone concentrations. The oestrus responses by 7 days were15.5%, 73.3% and 0%, for eCG, PG600, and control gilts, respectively (p < 0.001). The oestrus response improved (p < 0.05) with increasing body weight. Based on circulating progesterone levels, all oestrous gilts ovulated except for four of the PG600 gilts. Failure to express oestrus in PG600 gilts was not associated with a premature rise in progesterone.  相似文献   
86.
87.
A model is presented to determine the horizontal density distribution (HDD) and vertical density profile (VDP) of oriented strand board (OSB) panels produced by batch pressing. The HDD is simulated using input distributions of flake dimensions and orientation from plant measurements. Many previous HDD models rely on assumed distributions, which may not accurately characterize current manufacturing processes. The model predicts the VDP based on the compression behaviour of cellular materials in combination with temperature and moisture profiles calculated using a previously published heat and mass transport model. A novel empirical approach is applied rather than the time–temperature–moisture superposition method commonly used. The model predictions compare favourably with plant data and exhibit trends similar to previously reported experimental results. This work is the first of a two-part publication. The second part is concerned with stiffness property prediction and an optimization of the OSB manufacturing process. This work is novel in that no comprehensive model including HDD, VDP, stiffness property prediction and optimization has been reported in the literature.  相似文献   
88.
89.
90.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号